On Monday, Novo Nordisk initiated a global phase IIIa trial of semaglutide in tablet form, as a treatment for obesity, the pharmaceutical company confirms to MedWatch.
The phase IIIa trial, called Oasis 1, comes at a time when Novo Nordisk is already experiencing huge US demand for its newly-launched obesity drug Wegovy. In its own phase III trials, this drug demonstrated an average weight loss of 17-18 percent in participants without type 2 diabetes, and the two drugs are based on the same active ingredient, semaglutide - though Wegovy is administered via injection.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
CHMP recommends nine new drugs, rejects one
Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.
WS Audiology still chewing over listing of online hearing company
The hearing giant is still mulling over the independent listing of Hear.com.
CEO at WSA: No clarity on EQT exit plans yet
The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.
Oticon: Covid-19 led to debates about product launches
The unpredictable world situation in the spring of 2020 meant that the timing of product launches was frequently discussed at Demant-owned Oticon, located in Denmark.
EU Commission ends Danish HERA dreams – but could provide new opportunities for the pharmaceutical industry
With a budget potentially exceeding EUR 47.1bn (DKK 350bn), the EU Commission wants to establish a new agency to ward against future health crises. While the financial makeup is uncertain, good news for future clinical trials might be on the way.
Human Resources Senior Business Partner - Orifarm 
Medical Director (diabetes and obesity) - Zealand Pharma 
KLIFO is looking for an experienced and skilled Proposal Manager for one of our offices in Denmark, Sweden or Germany 
Associate Director/Senior Manager, Global Regulatory Affairs Project Lead - Genmab 
Project Manager, Adcendo ApS 
Employee of the regulatory department with knowledge of food safety and legislation within dietary supplements and medicines 
Bioinformatician / Immunoinformatician - Vaccibody 
Senior Clinical Research Specialist - Ambu 
Global Senior Medical Advisor – Neurology Pipeline Projects, Lundbeck 
Analytical Coordinator - Symphogen 
Medical Scientific Liaison Dermo aesthetic, IBSA 
Principal Scientist, Protein Drug Discovery & Development - Y-mAbs Therapeutics A/S 
Director of Communications – Evaxion Biotech 
A tech-savvy Project Manager Oncology (m/f/x) with a passion for communication and cross-functional collaboration - Daiichi-Sankyo